The Efficacy of Orally Administered GSK2190915 as an Add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils.
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Fiboflapon (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 11 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.